<DOC>
	<DOC>NCT00035854</DOC>
	<brief_summary>This study will treat pediatric patients who have infections that are due to a specific bacteria (Vancomycin-Resistant Enterococcus)</brief_summary>
	<brief_title>New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<criteria>Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary. Hospitalized/chronic care pediatric patients (birth through 17 years) Known infections due to vancomycinresistant enterococcus species, including diagnosis of hospitalacquired pneumonia, complicated skin and skin structure infections, catheterrelated bacteremia, bacteremia of unidentified source, and other infections Requires a minimum of 3 days of IV medication Patients with mixed infections due to VRE &amp; gram negative bacteria are allowed to enroll in the study. For most of the infections, 2 or more of additional symptoms are required. Potentially effective concomitant antibiotic A high surgical cure rate Medical conditions which would preclude clinical evaluation or require treatment of longer duration than 28 days 24 hours of antibiotic treatment within 48 hours of study entry (unless preapproved) Having an infected device that could not be removed</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Pharmacia</keyword>
	<keyword>Drug Resistance, Microbial</keyword>
</DOC>